Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)
Lee, Jae Hoon
Kim, Min Kyoung
Chng, Wee Joo
Kumar, Shaji K
MetadataShow full item record
SponsorsNational Natural Science Foundation of China
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/13965
Showing items related by title, author, creator and subject.
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 StudyFarooq, Asim V.; Degli Esposti, Simona; Popat, Rakesh; Thulasi, Praneetha; Lonial, Sagar; Nooka, Ajay K.; Jakubowiak, Andrzej; Sborov, Douglas; Zaugg, Brian E.; Badros, Ashraf Z.; et al. (Springer Science and Business Media LLC, 2020-07-25)Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody–drug conjugate (ADC; or immunoconjugate) that delivers a cytotoxic payload, monomethyl auristatin F (MMAF), to myeloma cells. In the phase II DREAMM-2 study (NCT03525678), single-agent belamaf (2.5 mg/kg) demonstrated clinically meaningful anti-myeloma activity (overall response rate 32%) in patients with heavily pretreated disease. Microcyst-like epithelial changes (MECs) were common, consistent with reports from other MMAF-containing ADCs. Methods: Corneal examination findings from patients in DREAMM-2 were reviewed, and the clinical descriptions and accompanying images (slit lamp microscopy and in vivo confocal microscopy [IVCM]) of representative events were selected. A literature review on corneal events reported with other ADCs was performed. Results: In most patients receiving single-agent belamaf (72%; 68/95), MECs were observed by slit lamp microscopy early in treatment (69% had their first event by dose 4). However, IVCM revealed hyperreflective material. Blurred vision (25%) and dry eye (15%) were commonly reported symptoms. Management of MECs included dose delays (47%)/reductions (25%), with few patients discontinuing due to MECs (1%). The first event resolved in most patients (grade ≥2 MECs and visual acuity[each 77%], blurred vision [67%], and dry eye [86%]), with no reports of permanent vision loss to date. A literature review confirmed that similar MECs were reported with other ADCs; however, event management strategies varied. The pathophysiology of MECs is unclear, though the ADC cytotoxic payload may contribute to on- or off-target effects on corneal epithelial cells. Conclusion: Single-agent belamaf represents a new treatment option for patients with RRMM. As with other ADCs, MECs were observed and additional research is warranted to determine their pathophysiology. A multidisciplinary approach, involving close collaboration between eye care professionals and hematologist/oncologists, is needed to determine appropriate diagnosis and management of these patients. Trial Registration: ClinicalTrials.gov Identifier, NCT03525678. © 2020, The Author(s).
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study (Ophthalmology and Therapy, (2020), 10.1007/s40123-020-00280-8)Farooq, Asim V.; Degli Esposti, Simona; Popat, Rakesh; Thulasi, Praneetha; Lonial, Sagar; Nooka, Ajay K.; Jakubowiak, Andrzej; Sborov, Douglas; Zaugg, Brian E.; Badros, Ashraf Z.; et al. (Springer Nature, 2020-09-12)The authors of the above mentioned article would like to highlight the corrections in https://doi.org/10.1007/s40123-020-00289-z, based upon recent changes to the FDA label and guidance on the use of belamaf.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myelomaShah, Nina; Aiello, Jack; Avigan, David E; Berdeja, Jesus G; Borrello, Ivan M; Chari, Ajai; Cohen, Adam D; Ganapathi, Karthik; Gray, Lissa; Green, Damian; et al. (BMJ, 2020-07-12)Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.